Knoll pricing Meridia at $2.90-$3.75 per day: high price may restrict anti-obesity use.
Executive Summary
KNOLL MERIDIA LAUNCH PRICE OF $2.90 PER DAY AWP SUGGESTS CONSERVATIVE APPROACH to marketing the once-daily obesity therapy. The price of Meridia (sibutramine) on a daily basis is more than 70% higher than the launch price for Wyeth-Ayerst/Interneuron's now-withdrawn Redux (dexfenfluramine), which cost $1.70 per day AWP. Knoll faces the same relatively unusual marketing challenge Wyeth faced with Redux: a desire to limit the roll-out of its drug to avoid an early spike in sales followed by a drop-off. The high-profile cardiovascular side effects associated with Redux and its predecessor product Pondimin (fenfluramine) has made the obesity market even more sensitive.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth